Taxonomy

CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT

Multisite and multiyear collaborative project led by a team of

Read More

2023 CMTA-STAR Celebrating our Collective Achievements

Significant Research Investment Made in 2023: We are excited to

Read More

ToolGen CMT1A Treatment Receives Orphan Drug Designation

CMTA Alliance Partner ToolGen announced December 18, 2023 that it

Read More

Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003

Published: December 11, 2023 French biopharmaceutical company Pharnext SA announced

Read More

Novartis Secures $1.3B Deal for CMT Treatment CKD-510

Novartis is making significant strides in the field of Charcot-Marie-Tooth

Read More

Therapeutic Inactivation of CMT2 Disease Alleles with CRISPR

New technologies in gene editing such as CRISPR/Cas9 present a

Read More

CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy

First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth

Read More

CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO

GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced

Read More

October 2023 Community Statement from Novartis

“The CMTA welcomes this community update from Novartis and applauds

Read More

CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E

The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28

Read More